Project outline. Brains contain billions of specialised cells, called neurons, which are the fundamental building blocks of every circuit in the nervous system. Read more
White matter impairments are a major component of various neurodegenerative diseases, including Alzheimer’s disease(1,2). White matter is composed of neuronal axons and their encasing myelin; a lipid-rich material produced by the oligodendroglia. Read more
The School has long-standing research collaborations with hospitals and medical centres worldwide developing new approaches to the diagnosis and monitoring of neurological conditions, including Parkinson’s and Alzheimer’s. Read more
Alzheimer’s disease (AD) affects around 50 million people globally with no cure. Apart from well-known neuronal loss, myelin abnormalities in brain have been recently detected from early stage of AD. Read more
Supervisors. Dr. Dan Ma, Lecturer in Biomedical Sciences, Aston Medical School, Aston University. Dr. Irundika Dias, Lecturer in Biomedical Sciences, Aston Medical School, Aston University. Read more
Background. Blood-brain barrier dysfunction in Alzheimer’s Disease (AD). The blood-brain barrier (BBB) is formed by a continuous layer of cerebral endothelial cells held together by tight junction proteins (TJP), which restrict the movement of molecules. Read more
Alzheimer’s disease (AD) is the most common cause of dementia worldwide. Current tools for monitoring AD pathology include neuroimaging biomarkers using MRI or PET and CSF biomarkers. Read more
Our lab is interested in understanding and treating a devastating neurodegenerative disorder, Alzheimer’s Disease (AD), in particular aspects relating to develop appropriate disease models for AD. Read more
Neurodegenerative disorders, such as Alzheimer’s disease, are often associated with chronic neuroinflammation and glial cell dysfunction that acts to exacerbate neuronal damage and loss of synapses. Read more
Epilepsy is the most common neurological condition in the UK, affecting 1 – 2 % of the population. Epilepsies often involve only a small area of the brain - the epileptic focus – and the abnormal activity can propagate out from there. Read more
Non-adherence to treatment costs the NHS more than £500M each year. Adherence is especially important when treating patients with chronic conditions that require lifetime pharmacological treatment, such as schizophrenia, Parkinson’s disease, HIV and Alzheimer’s disease. Read more
This project is one of 15 four year PhD Studentships funded by Medical Research Scotland (MRS) (. https://www.medicalresearchscotland.org.uk. Read more
The Alzheimer’s Society acknowledges the COVID-19 pandemic led to a significant decrease in dementia diagnosis rates from 67.6% in February 2020 to 63.5% in June 2020. Read more
The primary pathology of dementia with Lewy bodies (DLB) is alpha-synuclein, however multiple studies have demonstrated that Alzheimer’s disease (AD) related pathologies (tau and beta amyloid) play an important role in disease progression driving spread of pathology and accelerating cognitive decline. Read more
*Offer only available for the duration of your active subscription, and subject to change. You MUST claim your prize within 72 hours, if not we will redraw.
Create your myFindAPhD account to add this PhD to your shortlist to register for this event to receive updates on upcoming events
Due to your Facebook privacy settings, we were unable to create your account at this time. Please select another method to sign up.
We were unable to log you in with your Google account at this time. If you have third-party cookies blocked, please enable them, refresh, and try again.
We were unable to log you in with your Google account at this time. If you have third-party cookies blocked, please enable them, refresh, and try again.
Continue with Facebook
Looking to list your PhD opportunities? Log in here.